Key Insights

Highlights

Success Rate

65% trial completion

Published Results

15 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

10.1%

8 terminated out of 79 trials

Success Rate

65.2%

-21.3% vs benchmark

Late-Stage Pipeline

5%

4 trials in Phase 3/4

Results Transparency

100%

15 of 15 completed with results

Key Signals

15 with results65% success

Data Visualizations

Phase Distribution

67Total
Not Applicable (9)
Early P 1 (2)
P 1 (25)
P 2 (27)
P 3 (3)
P 4 (1)

Trial Status

Recruiting25
Active Not Recruiting16
Completed15
Withdrawn9
Terminated8
Suspended4

Trial Success Rate

65.2%

Benchmark: 86.6%

Based on 15 completed trials

Clinical Trials (79)

Showing 20 of 20 trials
NCT03987555Suspended

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

NCT01174121Phase 2Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT04550494Phase 2Active Not Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT05751668Phase 2Suspended

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

NCT02115282Phase 3Active Not Recruiting

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

NCT05372640Phase 1Recruiting

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT02849496Phase 2Active Not Recruiting

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT05092373Phase 1Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT06557148Active Not Recruiting

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

NCT07137416Phase 1Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT02364557Phase 2Completed

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT04316117Phase 2Active Not Recruiting

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT05534438Phase 2Recruiting

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT01463072Phase 2Active Not Recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

NCT01351909Phase 1Active Not Recruiting

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT05376878Phase 4Recruiting

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

NCT06500455Phase 3Recruiting

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500481Phase 3Recruiting

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT07664579Recruiting

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

NCT07158021Phase 2Recruiting

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

Scroll to load more

Research Network

Activity Timeline